BIG
CSTL icon

Brooklyn Investment Group’s Castle Biosciences CSTL Stock Holding History

Brooklyn Investment Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11
Closed -$225 – 1138
2025
Q2 		$225 Hold
11
– – ﹤0.01% 3178
2025
Q1 		$221 Buy
+11
New +$272 ﹤0.01% 2613

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brooklyn Investment Group's CSTL Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Castle Biosciences (CSTL) in Q3 2025, closing a stake of 11 shares — an estimated $225 sold.

Brooklyn Investment Group first reported a position in CSTL in Q1 2025 and held it in 2 quarters. The position peaked at $225 in Q2 2025. 173 funds tracked by Wall St. Rank hold CSTL as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Castle Biosciences position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 11 Castle Biosciences shares in Q3 2025, an estimated $225.
  • Brooklyn Investment Group first reported a position in Castle Biosciences in Q1 2025 and held it in 2 quarters.
  • Brooklyn Investment Group's Castle Biosciences position peaked at $225 in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.